Dacryocystitis Market - Forecast(2024 - 2030)

Report Code: HCR 1543 Report Format: PDF + Excel

Dacryocystitis Market Overview:

Dacryocystitis Market size is valued at $150 Million in 2022 and is expected to reach a value of $220 Million by 2030 at a CAGR of 4.50% during the forecast period 2023-2030. Dacryocystitis is a medical condition characterized by inflammation or infection of the lacrimal sac, which is a small pouch located in the inner corner of the eye. 

This sac collects tears and drains them into the nasal cavity. When the drainage system is blocked, it can lead to the accumulation of tears and provide a breeding ground for bacteria, resulting in inflammation and infection. At the time of my last update, dacryocystitis was generally treated through a combination of medical management and surgical intervention. The treatment approach might include antibiotics to control infection, warm compresses to alleviate symptoms, and surgical procedures such as dacryocystorhinostomy (DCR) to create a new drainage pathway for tears.

Market Snapshot: 

Dacryocystitis Market   - Report Coverage:

The “Dacryocystitis Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Motion Sickness Treatment Market.

Attribute

Segment

By Indication

  • Acute

  • Chronic

  • Other Indications

By Distribution Channel

  • Institutional Sales

  • Retail Sales

 

 

 

By Geography

  • North America (U.S., Canada and Mexico)

  • Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe),

  • Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific),

  • South America (Brazil, Argentina, Chile, Colombia and Rest of South America)

  • Rest of the World (Middle East and Africa).


Dacryocystitis Market- Top Trends Technological advancements: 

Minimally Invasive Procedures: There has been a trend towards minimally invasive techniques for treating dacryocystitis. Endoscopic dacryocystorhinostomy (DCR) is an example of such a procedure. This technique involves using an endoscope to create a new tear drainage pathway without making external incisions, which can lead to faster recovery and fewer complications.

Laser-Assisted Procedures: Laser technology has been explored for dacryocystitis treatment. Laser-assisted DCR is a technique that uses lasers to create the new tear drainage pathway, reducing the need for traditional incisions. This approach can offer precision and potentially quicker healing times.

Improved Imaging Techniques: Advanced imaging technologies like high-resolution ultrasound, optical coherence tomography (OCT), and magnetic resonance imaging (MRI) have been utilized to better visualize the lacrimal system's anatomy and guide treatment planning. These imaging techniques can aid in diagnosing the condition and determining the most suitable treatment approach.

Biocompatible Materials: In cases where surgical intervention is required, the development of biocompatible materials for stents or tubes placed within the tear drainage system can improve patient outcomes. These materials reduce the risk of stent-related complications and can be better tolerated by the body.

Personalized Treatment Plans: With advancements in medical imaging and diagnostic techniques, healthcare providers can tailor treatment plans to individual patients. This can lead to more effective and targeted interventions, ultimately improving patient outcomes and reducing the need for invasive procedures. 

Dacryocystitis Market - Company Product Analysis
Pharmaceutical Companies: Pharmaceutical companies might develop antibiotics or anti-inflammatory medications to treat dacryocystitis. These could include well-known companies like Pfizer, Novartis, or Johnson & Johnson.

Medical Device Companies: Medical device companies could produce instruments for procedures to treat dacryocystitis, such as lacrimal sac irrigation or surgery. These companies might include Medtronic, Bausch Health, or Carl Zeiss Meditec.

Biotechnology Companies: Biotech firms could develop innovative therapies or drugs targeting the underlying causes of dacryocystitis. These companies could include Genentech, Amgen, or Biogen.

Ophthalmology Companies: Companies specializing in ophthalmic products and treatments might have relevant products for dacryocystitis. Alcon, Allergan (now part of AbbVie), and Santen Pharmaceutical are examples.

Local or Regional Companies: Depending on your region, there might be local or regional companies that offer products specifically designed for treating dacryocystitis.

Key Market Players: 
Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Motion Sickness Treatment Market. The top 10 companies in this industry are listed below:
  1. Kaneka Corp.
  2. LABIANA GROUP
  3. Merck & Co. Inc.
  4. Mylan NV
  5. Nosch
  6. Novartis International AG
  7. Orex Pharma Pvt. Ltd.
  8. Perrigo Co.
  9. Pfizer Inc.
  10. PRODECO PHARMA Srl

Scope of Report: 

Report Metric

Details

Base Year Considered

2022

Forecast Period

2023–2030

CAGR

4.50%

Market Size in 2030

$220 Million

Segments Covered

By Indication, Distribution Channel, and Geography




Geographies Covered

North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa).






Key Market Players

  1. Akorn, Inc.

  2. Alembic Pharmaceuticals Ltd.

  3. Aurobindo Pharma Ltd.

  4. Bess Medizintechnik GmbH

  5. Cigna

  6. Cipla Ltd.

  7. Eyevance Pharmaceuticals

  8. Gunther Weiss Scientific Glass Co. Inc.

  9. FCI Ophthalmics

  10. GlaxoSmithKline Plc

 



For more Lifesciences and Healthcare Market reports, please click here

1. Dacryocystitis Market- Overview
    1.1. Definitions and Scope
2. Dacryocystitis Market- Executive Summary
3. Dacryocystitis Market- Comparative Analysis
    3.1. Company Benchmarking - Key Companies
    3.2. Global Financial Analysis - Key Companies
    3.3. Market Share Analysis - Key Companies
    3.4. Patent Analysis
    3.5. Pricing Analysis
4. Dacryocystitis Market- Start-up Companies Scenario (Premium)
    4.1. Key Start-up Company Analysis by
    4.2. Investment
    4.3. Revenue
    4.4. Venture Capital and Funding Scenario
5. Dacryocystitis Market– Market Entry Scenario Premium (Premium)
    5.1. Regulatory Framework Overview
    5.2. New Business and Ease of Doing Business Index
    5.3. Case Studies of Successful Ventures
6. Dacryocystitis Market- Forces
    6.1. Market Drivers
    6.2. Market Constraints
    6.3. Market Challenges
    6.4. Porter's Five Force Model
    6.5. Bargaining Power of Suppliers
    6.6. Bargaining Powers of Customers
    6.7. Threat of New Entrants
    6.8. Rivalry Among Existing Players
    6.9. Threat of Substitutes
7. Dacryocystitis Market– Strategic Analysis
    7.1. Value Chain Analysis
    7.2. Opportunities Analysis
    7.3. Market Life Cycle
8. Dacryocystitis Market– By Indication (Market Size – $Million/$Billion) 
    8.1. Acute
        8.1.1. Market Size and Forecast, By Region
        8.1.2. Market Share Analysis, By Country
    8.2. Chronic
        8.2.1. Market Size and Forecast, By Region
        8.2.2. Market Share Analysis, By Country
    8.3. Other Indications
        8.3.1. Market Size and Forecast, By Region
        8.3.2. Market Share Analysis, By Country
9. acryocystitis Market– By Distribution Channel (Market Size – $Million/$Billion) 
    9.1. Institutional Sales
        9.1.1. Market Size and Forecast, By Region
        9.1.2. Market Share Analysis, By Country
    9.2. Retail Sales
        9.2.1. Market Size and Forecast, By Region
        9.2.2. Market Share Analysis, By Country
10. Dacryocystitis Market– by Geography (Market Size – $Million/$Billion) 
    10.1. North America
        10.1.1. The U.S.
        10.1.2. Canada
        10.1.3. Mexico
    10.2. Europe
        10.2.1. UK
        10.2.2. Germany
        10.2.3. France
        10.2.4. Italy
        10.2.5. Spain
        10.2.6. Russia
        10.2.7. Rest of Europe
    10.3. Asia-Pacific
        10.3.1. China
        10.3.2. India
        10.3.3. Japan
        10.3.4. South Korea
        10.3.5. Australia & New Zealand
        10.3.6. Rest of Asia-Pacific
    10.4. South America
        10.4.1. Brazil
        10.4.2. Argentina
        10.4.3. Chile
        10.4.4. Colombia
        10.4.5. Rest of South America
    10.5. Rest of the World
        10.5.1. Middle East
        10.5.2. Africa
11. Dacryocystitis Market– Entropy
12. Dacryocystitis Market– Industry/Segment Competition Landscape Premium 
    12.1. Market Share Analysis
        12.1.1. Market Share by Product Type – Key Companies
        12.1.2. Market Share by Region – Key Companies
        12.1.3. Market Share by Country – Key Companies
    12.2. Competition Matrix
    12.3. Best Practices for Companies
13. Dacryocystitis Market– Key Company List by Country Premium Premium 
14. Dacryocystitis Market- Company Analysis
    14.1. Akorn, Inc.
    14.2. Alembic Pharmaceuticals Ltd.
    14.3. Aurobindo Pharma Ltd.
    14.4. Bess Medizintechnik GmbH
    14.5. Cigna
    14.6. Cipla Ltd.
    14.7. Eyevance Pharmaceuticals
    14.8. Gunther Weiss Scientific Glass Co. Inc.
    14.9. FCI Ophthalmics
    14.10. GlaxoSmithKline Plc
    14.11. Kaneka Corp.
    14.12. LABIANA GROUP
    14.13. Merck & Co. Inc.
    14.14. Mylan NV
    14.15. Nosch
    14.16. Novartis International AG
    14.17. Orex Pharma Pvt. Ltd.
    14.18. Perrigo Co.
    14.19. Pfizer Inc.
    14.20. PRODECO PHARMA Srl

"Financials to the Private Companies would be provided on best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our 
reports include global-level data, niche markets and competitive landscape.



The Dacryocystitis is forecast to grow at 4.50% during the forecast period 2023-2030.

Global Dacryocystitis Market size is estimated to reach $220 Million by 2030.

The leading players in the Dacryocystitis Market are Akorn,Inc., Alembic Pharmaceuticals, Ltd.Aurobindo Pharma Ltd., Bess Medizintechnik GmbH, Cigna